Surrozen, Inc. (NASDAQ:SRZN) Short Interest Up 43.0% in November

Surrozen, Inc. (NASDAQ:SRZN) saw a significant increase in short interest during the month of November. As of November 30th, there was short interest totalling 33,900 shares, an increase of 43.0% from the November 15th total of 23,700 shares. Based on an average daily volume of 29,300 shares, the days-to-cover ratio is presently 1.2 days. Currently, 1.4% of the shares of the company are sold short.

Surrozen Price Performance

Shares of NASDAQ SRZN traded up $0.14 during trading hours on Friday, hitting $9.85. 24,834 shares of the company’s stock were exchanged, compared to its average volume of 17,884. The company’s 50-day moving average price is $10.29 and its 200-day moving average price is $9.74. Surrozen has a 1-year low of $6.00 and a 1-year high of $16.19.

Surrozen (NASDAQ:SRZN) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($2.77) by $2.33. The business had revenue of $10.00 million for the quarter. Research analysts anticipate that Surrozen will post -7.16 EPS for the current year.

Institutional Trading of Surrozen

Hedge funds and other institutional investors have recently bought and sold shares of the stock. CVI Holdings LLC acquired a new stake in Surrozen during the second quarter worth about $711,000. Stonepine Capital Management LLC acquired a new stake in shares of Surrozen during the 2nd quarter worth approximately $724,000. Nantahala Capital Management LLC bought a new stake in shares of Surrozen during the second quarter valued at approximately $2,050,000. Finally, Armistice Capital LLC acquired a new position in shares of Surrozen in the second quarter valued at $2,080,000. 66.57% of the stock is currently owned by institutional investors and hedge funds.

About Surrozen

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.